Skip to main content
. 2017 Sep 19;8:1150. doi: 10.3389/fimmu.2017.01150

Figure 6.

Figure 6

Combinations of immunomodulatory tumor-derived vaccines prevent tumor progression in previously cured and subsequently rechallenged animals. Thirty days after the first challenge, animals that were free of tumors were rechallenged with parental B16F10 cells. The graph shows the cumulative survival curves for three independent experiments (n = 12 mice per group). The survival curves were analyzed using the Log-rank test.